Colorectal cancer is the second-leading cause of cancer-related death in the U.S., even though it is highly treatable if caught early.2 The American Cancer Society estimates that more than 150,000 ...

Guardant Health aims to reshape how the U.S. gets screened for colorectal cancer, by claiming a groundbreaking FDA approval for a tumor-detecting blood test aimed at a population of about 120 million ...

Shield Across America mobile screening tour launches during Colorectal Cancer Awareness Month to address nation’s dangerously low screening rates by bringing Shield blood test directly to Americans ...

FDA approval of a Guardant Health blood test that screens for colorectal cancer makes it the first liquid biopsy approved for this type of cancer, clearing the way to make this test more accessible to ...

Living in rural Colorado means long days, hard work, and taking care of the people and land we love. Whether you’re tending crops, working cattle, raising a family, or enjoying retirement, your health ...

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Quest Diagnostics (NYSE:DGX) is partnering with Guardant Health to offer Shield, an ...

The Food and Drug Administration on Monday approved Guardant Health’s blood test, called Shield, to screen for colon cancer. The test isn't meant to replace colonoscopies, but is generating enthusiasm ...

Strategic collaboration to enable streamlined and accelerated access to Shield blood-based colorectal cancer screening test across Quest’s vast network Physicians nationwide now have the ability to ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of Shield Across America, a historic coast-to-coast mobile ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the Shield™ by Guardant blood-based screening test is now widely accessible for physician order through ...